Prospective Multi-centre Studies of Prognostic Factors in Castration Resistant PROState Cancer Treated With Radium-223

Trial Profile

Prospective Multi-centre Studies of Prognostic Factors in Castration Resistant PROState Cancer Treated With Radium-223

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms PRORADIUM
  • Most Recent Events

    • 12 Sep 2017 48 centres are recruiting for this trial and 54 patients have been included, as reported in an abstract presented at the 42nd European Society for Medical Oncology Congress. This trial is funded by Bayer Hispania.
    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top